Research Article

You have full text access to this OnlineOpen article

Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant†

  1. Paul M. Barr1,*,
  2. Hillard M. Lazarus1,
  3. Brenda W. Cooper1,
  4. Mark D. Schluchter2,
  5. Ashok Panneerselvam2,
  6. James W. Jacobberger3,
  7. Jack W. Hsu4,
  8. Nalini Janakiraman5,
  9. Aleksandra Simic6,
  10. Afshin Dowlati1,
  11. Scot C. Remick7

Article first published online: 11 MAY 2009

DOI: 10.1002/ajh.21449

Issue

American Journal of Hematology

American Journal of Hematology

Volume 84, Issue 8, pages 484–487, August 2009

Additional Information

How to Cite

Barr, P. M., Lazarus, H. M., Cooper, B. W., Schluchter, M. D., Panneerselvam, A., Jacobberger, J. W., Hsu, J. W., Janakiraman, N., Simic, A., Dowlati, A. and Remick, S. C. (2009), Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. Am. J. Hematol., 84: 484–487. doi: 10.1002/ajh.21449

Author Information

  1. 1

    Department of Medicine, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio

  2. 2

    Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio

  3. 3

    Department of Genetics, Case Western Reserve University, Cleveland, Ohio

  4. 4

    Department of Medicine, University of Florida Shands Cancer Center, Gainesville, Florida

  5. 5

    Department of Medicine, Henry Ford Medical Center, Detroit, Michigan

  6. 6

    Department of Medicine, Oregon Health Sciences University, Portland, Oregon

  7. 7

    Department of Medicine, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, West Virginia

*University Hospitals Case Medical Center, Case Western Reserve University, 11100 Euclid Ave, WRN 5065, Cleveland, OH 44106

  1. †

    Conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 24 JUL 2009
  2. Article first published online: 11 MAY 2009
  3. Accepted manuscript online: 11 MAY 2009 12:00AM EST
  4. Manuscript Accepted: 4 MAY 2009
  5. Manuscript Revised: 1 MAY 2009
  6. Manuscript Received: 10 MAR 2009

Funded by

  • National Institutes of Health. Grant Numbers: CA62502, M01-RR-00080

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (115K)

References

  • 1
    Philip T,Guglielmi C,Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.
  • 2
    Schouten HC,Qian W,Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927.
  • 3
    Berkow RL,Kraft AS. Bryostatin. A non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor. Biochem Biophys Res Commun 1985; 131: 1109–1116.
  • 4
    May WS,Sharkis SJ,Esa AH, et al. Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. Proc Natl Acad Sci USA 1987; 84: 8483–8487.
  • 5
    Tallant EA,Smith JB,Wallace RW. Bryostatins mimic the effects of phorbol esters in intact human platelets. Biochim Biophys Acta 1987; 929: 40–46.
  • 6
    Drexler HG,Gignac SM,Jones RA, et al. Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood 1989; 74: 1747–1757.
  • 7
    McCrady CW,Staniswalis J,Pettit GR, et al. Effect of pharmacologic manipulation of protein kinase C by phorbol dibutyrate and bryostatin 1 on the clonogenic response of human granulocyte-macrophage progenitors to recombinant GM-CSF. Br J Haematol 1991; 77: 5–15.
  • 8
    Berkow RL,Schlabach L,Dodson R, et al. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res 1993; 53: 2810–2815.
  • 9
    Scheid C,Prendiville J,Jayson G, et al. Immunomodulation in patients receiving intravenous bryostatin 1 in a phase I clinical study: Comparison with effects of bryostatin 1 on lymphocyte function in vitro. Cancer Immunol Immunother 1994; 39: 223–230.
  • 10
    Bosco MC,Rottschafer S,Taylor LS, et al. The antineoplastic agent bryostatin-1 induces proinflammatory cytokine production in human monocytes: Synergy with interleukin-2 and modulation of interleukin-2Rgamma chain expression. Blood 1997; 89: 3402–3411.
  • 11
    Philip PA,Rea D,Thavasu P, et al. Phase I study of bryostatin 1: Assessment of interleukin 6 and tumor necrosis factor α induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst 1993; 85: 1812–1818.
  • 12
    Prendiville J,Crowther D,Thatcher N, et al. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 1993; 68: 418–424.
  • 13
    Jayson GC,Crowther D,Prendiville J, et al. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 1995; 72: 461–468.
  • 14
    Marshall JL,Bangalore N,El-Ashry D, et al. Phase I study of prolonged infusion bryostatin-1 in patients with advanced malignancies. Cancer Biol Ther 2002; 1: 409–416.
  • 15
    Varterasian ML,Mohammad RM,Shurafa MS, et al. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res 2000; 6: 825–828.
  • 16
    Blackhall FH,Ranson M,Radford JA, et al. A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. Br J Cancer 2001; 84: 465–469.
  • 17
    al-Katib A,Mohammad RM,Mohamed AN, et al. Conversion of high grade lymphoma tumor cell line to intermediate grade with TPA and bryostatin 1 as determined by polypeptide analysis on 2D gel electrophoresis. Hematol Oncol 1990; 8: 81–89.
  • 18
    Hornung RL,Pearson JW,Beckwith M,Longo DL. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: In vitro versus in vivo activity. Cancer Res 1992; 52: 101–107.
  • 19
    Mohammad RM,al-Katib A,Pettit GR,Sensenbrenner LL. Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines. Leuk Res 1993; 17: 1–8.
  • 20
    Mohammad RM,al-Katib A,Pettit GR,Sensenbrenner LL. Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res 1994; 54: 165–168.
  • 21
    Mohammad RM,Wall NR,Dutcher JA,Al-Katib AM. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large Cell lymphoma xenograft model. Clin Cancer Res 2000; 6: 4950–4956.
  • 22
    Wang S,Wang Z,Dent P,Grant S. Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cells. Blood 2003; 101: 3648–3657.
  • 23
    Cartee L,Maggio SC,Smith R, et al. Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol. Mol Cancer Ther 2003; 2: 83–93.
  • 24
    Al-Katib AM,Smith MR,Kamanda WS, et al. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 1998; 4: 1305–1314.
  • 25
    Mohammad RM,Diwakaran H,Maki A, et al. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk Res 1995; 19: 667–673.
  • 26
    Dowlati A,Lazarus HM,Hartman P, et al. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies. Clin Cancer Res 2003; 9: 5929–5935.
  • 27
    Wender PA,Dechristopher BA,Schrier AJ. Efficient synthetic access to a new family of highly potent bryostatin analogues via a Prins-driven macrocyclization strategy. J Am Chem Soc 2008; 130: 6658–6659.
  • 28
    Roberts JD,Smith MR,Feldman EJ, et al. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma. Clin Cancer Res 2006; 12: 5809–5816.
  • 29
    Wojciechowski W,Li H,Marshall S, et al. Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms. J Immunol 2005; 174: 7859–7868.
  • 30
    Tsai P-C,Hernandez-Ilizaliturri FJ,Olejniczak SH, et al. Modulation of CD20 expression in rituximab-sensitive (RSCL) and rituximab resistant cell lines (RRCL) using IL-4 and bryostatin-1. Blood 2007; 110: 2619.
  • 31
    Cheson BD,Horning SJ,Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored international working group. J Clin Oncol 1999; 17: 1244.
  • 32
    Simon R. Clinical trials in cancer. In: DevitaVT, HellmanS, RosenbergSA, editors. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott, Williams and Wilkins; 2001. pp 521–538.
  • 33
    Kaplan EL,Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
Get PDF (115K)